Exelixis
EXEL
#1700
Rank
NZ$16.87 B
Marketcap
$59.08
Share price
0.29%
Change (1 day)
70.47%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of September 2024 : NZ$3.86 Billion

According to Exelixis's latest financial reports the company has NZ$3.86 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$NZ$3.57 B-8.66%
2022-12-31$NZ$3.91 B21.1%
2021-12-31$NZ$3.23 B24.27%
2020-12-31$NZ$2.60 B4.03%
2019-12-31$NZ$2.50 B30.43%
2018-12-31$NZ$1.91 B378.36%
2017-12-31$NZ$0.40 B211.17%
2016-12-31$NZ$0.12 B-162.68%
2015-12-31$-NZ$0.21 Billion40.38%
2014-12-31$-NZ$0.15 Billion-281.82%
2013-12-31$NZ$80.6 M-77.63%
2012-12-31$NZ$0.36 B210.3%
2011-12-31$NZ$0.11 B-139.24%
2010-12-31$-NZ$0.3 Billion31.29%
2009-12-31$-NZ$0.23 Billion132.51%
2008-12-31$-NZ$96.95 Million-186.84%
2007-12-31$NZ$0.11 B-13.2%
2006-12-31$NZ$0.12 B53.43%
2005-12-31$NZ$83.82 M18.04%
2004-12-31$NZ$71.01 M-71.41%
2003-12-31$NZ$0.24 B-26.1%
2002-12-31$NZ$0.33 B-41.16%
2001-12-31$NZ$0.57 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
NZ$30.60 B 691.26%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$133.02 B 3,339.00%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$75.75 B 1,858.32%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$29.24 B 655.90%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$12.79 B 230.80%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$119.26 B 2,983.30%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$157.34 B 3,967.73%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$1.18 Million-100.03%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$49.03 M-98.73%๐Ÿ‡บ๐Ÿ‡ธ USA